Can pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O+) be added to standard treatment for resectable high-risk gastric cancer patients? A study protocol.

Autor:	Reid JL; Discipline of Surgery, The University of Adelaide, The Queen Elizabeth Hospital, Adelaide, SA, Australia., Kanhere HA; Discipline of Surgery, The University of Adelaide, The Queen Elizabeth Hospital, Adelaide, SA, Australia., Hewett PJ; Discipline of Surgery, The University of Adelaide, The Queen Elizabeth Hospital, Adelaide, SA, Australia., Price TJ; Department of Oncology, The Queen Elizabeth Hospital, Adelaide, SA, Australia.; Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia., Maddern GJ; Discipline of Surgery, The University of Adelaide, The Queen Elizabeth Hospital, Adelaide, SA, Australia., Trochsler MI; Discipline of Surgery, The University of Adelaide, The Queen Elizabeth Hospital, Adelaide, SA, Australia.; Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, Australia.
Jazyk:	angličtina
Zdroj:	Pleura and peritoneum [Pleura Peritoneum] 2021 Sep 17; Vol. 6 (4), pp. 151-154. Date of Electronic Publication: 2021 Sep 17 (Print Publication: 2021).
DOI:	10.1515/pp-2021-0132
Abstrakt:	Objectives: Gastric cancer remains one of the most fatal cancers, despite an intensive treatment regime of chemotherapy-surgery-chemotherapy. Peritoneal metastatic disease is commonly diagnosed post treatment regime and once established, patients are likely to die in 3-9 months. Systemic chemotherapy does not increase survival for these patients due to the poor vascularisation of this area. We are proposing the addition of pressurised intraperitoneal aerosol chemotherapy (PIPAC) to the treatment regime for curative patients as a preventive measure to reduce the risk of peritoneal metastases occurring. Methods: This is a prospective, single centre, non-randomised, open-label pilot trial evaluating the addition of PIPAC to the standard multimodal treatment pathway. Patients will undergo standard neoadjuvant chemotherapy with four cycles of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT), then PIPAC, followed by gastrectomy. Four cycles of FLOT will be administered post-surgery. Primary outcome is safety and feasibility, assessed by perioperative morbidity and possible interruptions of the standard multimodal treatment pathway. Competing Interests: Competing interests: Authors state no conflict of interest. (© 2021 Jessica L. Reid et al., published by De Gruyter, Berlin/Boston.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu